Therefore, the attenuation of oxidative stress and ROS to suppress CD36-mediated TLR4/6-IRAK4/1 signaling and NLRP3 inflammasome activation by cinnamaldehyde and allopurinol may be a promising therapeutic strategy for the treatment of metabolic syndrome-associated heart disease. Here, NLRP3 is linked to heart disorder.